CoChat

Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer

Open access

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Tumor-associated macrophages (TAMs) play a role in tumor development and progression. We hypothesized that abundance of TAMs might modify efficacy of 5-fluorouracil chemotherapy in colorectal cancer. We measured the density of CD68+ TAMs at the invasive front of primary tumor of colorectal carcinoma (PT-TAMs; n = 208), at available matched metastatic lymph node (LN-TAMs; n = 149), and in an independent set of primary colorectal cancers (PT-TAMs, n = 111). The hazard ratios for disease-free survival were computed by Cox proportional-hazards model. In exploratory analysis, the interaction between TAMs and 5-fluorouracil adjuvant therapy was significant (PT-TAMs, p = 0.02; LN-TAMs, p = 0.005). High TAMs were independently associated with better disease-free survival only in 5-fluorouracil-treated patients (PT-TAMs, HR 0.23; 95%CI, 0.08–0.65; p = 0.005; LN-TAMs, HR 0.13; 95%CI, 0.04–0.43; p = 0.001). The independent predictive value of PT-TAMs was replicated in the external set (HR, 0.14; 95%CI 0.02–1.00; p = 0.05). In an in vitro experiment, 5-fluorouracil and macrophages showed a synergistic effect and increased colorectal cancer cell death. High densities of TAMs, particularly in metastatic lymph-nodes, identify stage III colorectal cancer patients benefitting from 5-fluorouracil adjuvant therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2017.1342918

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Disease-free survival (DFS) in stage III colorectal cancer, by TAM-density quartiles. Kaplan-Meier Curves. Patients were stratified by quartile distribution of TAMs densities at the invasive front of their primary tumor (PT-TAMs, upper panels) or of metastatic lymph-nodes (LN-TAMs, lower panels). Higher densities of both PT-TAMs and LN-TAMs were significantly associated with better disease-free survival in patients treated with 5-fluorouracil (left panels), but not in the subset of untreated patients (right panels). Also higher densities of tumor-associated neutrophils (PT-TANs) were weakly associated with the survival of 5-fluorouracil -treated patients (see Fig. S1). P values are for Log-Rank test.
Figure 1. Disease-free survival (DFS) in stage III colorectal cancer, by TAM-density quartiles. Kaplan-Meier Curves. Patients were stratified by quartile distribution of TAMs densities at the invasive front of their primary tumor (PT-TAMs, upper panels) or of metastatic lymph-nodes (LN-TAMs, lower panels). Higher densities of both PT-TAMs and LN-TAMs were significantly associated with better disease-free survival in patients treated with 5-fluorouracil (left panels), but not in the subset of untreated patients (right panels). Also higher densities of tumor-associated neutrophils (PT-TANs) were weakly associated with the survival of 5-fluorouracil -treated patients (see Fig. S1). P values are for Log-Rank test.CC BY-NC-ND · PubMed Central
Figure 2. Disease-free survival (DFS) in 5-fluorouracil-treated patients with stage III colorectal cancer, by high/low TAMs. Kaplan-Meier Curves. Patients were classified by high/low density of TAMs, measured at the invasive front of their primary colorectal cancer (PT-TAMs) or of metastatic lymph-nodes (LN-TAMs), and defined by optimal cut-offs at receiver operator characteristic (ROC) curves (Fig. S2). P values are for Log-Rank test. Also high densities of intra-tumoral neutrophils (PT-TANs) were weakly (p = 0.04) associated with better disease-free survival (Fig. S3). The association of high PT-TAMs with better disease-specific survival was confirmed in the external validation set (Fig. S4).
Figure 2. Disease-free survival (DFS) in 5-fluorouracil-treated patients with stage III colorectal cancer, by high/low TAMs. Kaplan-Meier Curves. Patients were classified by high/low density of TAMs, measured at the invasive front of their primary colorectal cancer (PT-TAMs) or of metastatic lymph-nodes (LN-TAMs), and defined by optimal cut-offs at receiver operator characteristic (ROC) curves (Fig. S2). P values are for Log-Rank test. Also high densities of intra-tumoral neutrophils (PT-TANs) were weakly (p = 0.04) associated with better disease-free survival (Fig. S3). The association of high PT-TAMs with better disease-specific survival was confirmed in the external validation set (Fig. S4).CC BY-NC-ND · PubMed Central
Figure 3. Chemotherapy and macrophage synergism in cytotoxic function in vitro. A) Facs plots of SW480 colorectal cancer cells co-cultured with un-polarized (M0) or macrophages polarized toward a cytotoxic phenotype by IFNg/LPS stimulation (M1). Tumor cell death was evaluated by Annexin V/7-AAD staining. 24-hour 5-fluorouracil treatment on colorectal cancer cells alone did not significantly increase tumor cell death compared with untreated cells (top). Macrophages induced detectable tumor cell death, which was further enhanced by treatment with 5-fluorouracil (bottom). One representative of 5 experiments is shown. B) Histograms representative of 3 independent experiments performed with 2 MSS cell lines (SW480 and HT29): cytotoxicity of M1 macrophages toward colorectal cancer cells (*; P ≤ 0.05) was significantly increased by the addition of 5-fluorouracil in the 2 microsatellite stable cell lines, SW480 (**; P ≤ 0.005) and HT29 (***P ≤ 0.001). Histograms show means ± standard error. C) Culture of macrophages with supernatant of 5-fluorouracil-treated colorectal cancer cells (MfCM) significantly increased macrophage cytotoxicity (right) compared with control macrophages (left) or macrophages cultured with supernatant of control colorectal cancer cells (MfCT) (middle). One representative of 2 experiments is shown. D) Histograms representative of 2 independent experiments (***; P ≤ 0.001; **; p ≤ 0.01). E) Effect of chemotherapy on macrophage polarization markers. 5-Fluorouracil treatment of M0 macrophages increased the expression of the M1-marker HLA-DR, while the M2-marker CD163 did not shown any change. F) Effect of chemotherapy on macrophages-M1 cytotoxicity. TRAIL and TNFa expression was measured by ELISA in cellular extracts from macrophages stimulated with LPS/IFNg and subsequently exposed to 5-fluorouracil for 24 hours. One representative of 2 experiments is shown. Bars represent means ± standard error. (*: p <0.05; **: p ≤ 0.01).
Figure 3. Chemotherapy and macrophage synergism in cytotoxic function in vitro. A) Facs plots of SW480 colorectal cancer cells co-cultured with un-polarized (M0) or macrophages polarized toward a cytotoxic phenotype by IFNg/LPS stimulation (M1). Tumor cell death was evaluated by Annexin V/7-AAD staining. 24-hour 5-fluorouracil treatment on colorectal cancer cells alone did not significantly increase tumor cell death compared with untreated cells (top). Macrophages induced detectable tumor cell death, which was further enhanced by treatment with 5-fluorouracil (bottom). One representative of 5 experiments is shown. B) Histograms representative of 3 independent experiments performed with 2 MSS cell lines (SW480 and HT29): cytotoxicity of M1 macrophages toward colorectal cancer cells (*; P ≤ 0.05) was significantly increased by the addition of 5-fluorouracil in the 2 microsatellite stable cell lines, SW480 (**; P ≤ 0.005) and HT29 (***P ≤ 0.001). Histograms show means ± standard error. C) Culture of macrophages with supernatant of 5-fluorouracil-treated colorectal cancer cells (MfCM) significantly increased macrophage cytotoxicity (right) compared with control macrophages (left) or macrophages cultured with supernatant of control colorectal cancer cells (MfCT) (middle). One representative of 2 experiments is shown. D) Histograms representative of 2 independent experiments (***; P ≤ 0.001; **; p ≤ 0.01). E) Effect of chemotherapy on macrophage polarization markers. 5-Fluorouracil treatment of M0 macrophages increased the expression of the M1-marker HLA-DR, while the M2-marker CD163 did not shown any change. F) Effect of chemotherapy on macrophages-M1 cytotoxicity. TRAIL and TNFa expression was measured by ELISA in cellular extracts from macrophages stimulated with LPS/IFNg and subsequently exposed to 5-fluorouracil for 24 hours. One representative of 2 experiments is shown. Bars represent means ± standard error. (*: p <0.05; **: p ≤ 0.01).CC BY-NC-ND · PubMed Central
Figure 4. Immunostaining of CD68+ TAMs at the invasive margin of primary colorectal cancer (A) and of metastatic lymph-nodes (B). Examples of tissue areas with variable extent of CD68-immunoreative area (% IRA in white boxes).
Figure 4. Immunostaining of CD68+ TAMs at the invasive margin of primary colorectal cancer (A) and of metastatic lymph-nodes (B). Examples of tissue areas with variable extent of CD68-immunoreative area (% IRA in white boxes).CC BY-NC-ND · PubMed Central
Figure 5. Capture of immune reactive areas at image analysis. Example of computer assisted selection of immune reactive areas spots by red green and blue (RGB) color segmentation of the original digital microphotograph. Immune-reactive area, brown. Not stained tissue, yellow. The percent ratio between immune reactive areas and total area was automatically calculated.
Figure 5. Capture of immune reactive areas at image analysis. Example of computer assisted selection of immune reactive areas spots by red green and blue (RGB) color segmentation of the original digital microphotograph. Immune-reactive area, brown. Not stained tissue, yellow. The percent ratio between immune reactive areas and total area was automatically calculated.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 128

Metadata

Authors
Malesci, A., Bianchi, P., Celesti, G., Basso, G., Marchesi, F., Grizzi, F., Di Caro, G., Cavalleri, T., Rimassa, L., Palmqvist, R., Lugli, A., Koelzer, V. H., Roncalli, M., Mantovani, A., Ogino, S., & Laghi, L.
Affiliations
  • University of Milan (IT)
  • Fondazione Humanitas per la Ricerca (IT)
  • Humanitas University (IT)
  • Department of Immunology and Inflammation, Humanitas Clinical and Research Center, via Manzoni 113, Rozzano (Milan), Italy
  • Humanitas Cancer Center, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano 20089 (Milan), Italy
  • Umeå University (SE)
  • University of Bern (CH)
  • Brigham and Women's Hospital (US)
Corresponding author
  • Malesci, Alberto
  • Laghi, Luigi
Venue
OncoImmunology
Published
2017-07-12
Volume
6
Issue
12
Pages
e1342918
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2735116030
Cited by
124
References
51
Citations by year
2026: 4 · 2025: 8 · 2024: 11 · 2023: 13 · 2022: 10 · 2021: 23 · 2020: 29 · 2019: 15 · 2018: 9 · 2017: 2
FWCI
6.81
Type
journal article
Language
en
Open access
Locations
  • OncoImmunology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc-nd)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • DiVA at Umeå University (Umeå University) (submittedVersion, other-oa)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • BORIS (University Library Bern) (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by-nc-nd)
  • Zurich Open Repository and Archive (University of Zurich)
  • Open Access CRIS of the University of Bern
Funders
National Cancer Institute (R35CA197735)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
tumor-associated macrophages, 5-fluorouracil, adjuvant chemotherapy, stage III colorectal cancer, CD68, metastatic lymph nodes, disease-free survival, predictive biomarkers, chemotherapy response, tumor microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer. https://app.cochat.ai/papers/10.1080/2162402x.2017.1342918
The paper
Malesci, A., Bianchi, P., Celesti, G., Basso, G., Marchesi, F., Grizzi, F., Di Caro, G., Cavalleri, T., Rimassa, L., Palmqvist, R., Lugli, A., Koelzer, V. H., Roncalli, M., Mantovani, A., Ogino, S., & Laghi, L. (2017). Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer. OncoImmunology. https://doi.org/10.1080/2162402x.2017.1342918

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.